Trinity Biotech (TRIB) Receivables (2014 - 2025)

Trinity Biotech's Receivables history runs 12 years deep, the most recent figure standing at $11.5 million for Q4 2025.

• In Q4 2025, Receivables fell 15.37% year-over-year to $11.5 million; the TTM figure through Dec 2025 stood at $11.5 million (down 15.37% YoY), while the FY2025 annual figure was $11.5 million, down 15.37% from the prior year.
• Receivables came in at $11.5 million for Q4 2025 at Trinity Biotech, down from $13.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $2.7 billion in Q4 2022 to a low of $1.4 million in Q4 2023.
• A 5-year average of $544.1 million and a median of $11.5 million in 2025 frame the typical range for Receivables.
• Across the five-year window, Receivables surged 90020.56% in 2022 and sank 99.95% in 2023, its largest moves.
• Trinity Biotech's Receivables stood at $3.0 million in 2021, then soared by 90020.56% to $2.7 billion in 2022, then tumbled by 99.95% to $1.4 million in 2023, then jumped by 859.32% to $13.6 million in 2024, then slipped by 15.37% to $11.5 million in 2025.
• According to Business Quant data, Receivables over the past three periods registered $11.5 million, $13.6 million, and $1.4 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison